SAFETY &
TOLERABILITY

EMFLAZA® safety profile

EMFLAZA does have a risk of side effects. Please seek treatment immediately and tell your child's healthcare provider if your child has any of these symptoms or any other side effects.

This the group background image
Common side effects with EMFLAZADeflazacort 0.9 mg/kg/day (n=51) % at 12 weeksPlacebo (n=50) % at 12 weeksa
Facial puffiness or Cushingoid appearance33%12%
Weight increased20%6%
Increased appetite14%2%
Cough12%10%
Frequent daytime urinatioan12%6%
Upper respiratory tract infection12%2%
Unwanted hair growth 10%6%
Central obesity10%2%
Common cold10%4%
Irritability8%6%
Runny nose8%4%
Skin redness8%0%
Abdominal discomfort6%2%
  1. At 12 weeks placebo patients were re-randomized to receive either EMFLAZA or an active comparator.

More time on treatment may mean more time experiencing results

In a clinical study, fewer patients taking deflazacort experienced side effects than patients taking prednisone.

Changes in behavior are common with corticosteroid therapy in boys with Duchenne and can often lead to treatment changes or modifications

  • Boys taking deflazacort were less likely to experience psychiatric side effects such as abnormal behavior, aggression, irritability, and mood swings compared with those taking prednisone

Weight gain may negatively impact the ability to walk for children with Duchenne

  • Boys taking deflazacort also gained less weight compared with those taking prednisone (5% increase in body weight vs 18%)
  • More boys taking deflazacort experienced cataracts compared with those taking prednisone (4.4% vs 1.6%)